Therapeutic Evaluation of Palbociclib and Its Compatibility with Other Chemotherapies in Primary and Recurrent Nasopharyngeal Carcinoma

Xue, Zhichao; Lui, Vivian Wai Yan; Li, Yongshu; Lin, Jieyu; You, Chanping; Piao, Wenyin; Yuan, Hui; Khong, Pek Lan; Lo, Kwok Wai; Cheung, Lydia W.T.; Tsao, Sai Wah; Tsang, Chi Man

doi:10.21203/rs.3.rs-36929/v1

Cited by 4 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). This nding is consistent with previous studies done by Tsao's group [33]. Similar trend was also reported in colorectal cancer [34] and breast cancer [35], and the reason could be: cancer cells which were injected into the mouse, could interact with the local environment in three-dimensions and have easy access to the nutrients and oxygen, thus resulting in fast tumour growth [36].…”

Section: Discussionsupporting

confidence: 91%

Longitudinal evaluation of five nasopharyngeal carcinoma animal models on the microPET/MR platform

Shi

Xue

Tan

et al. 2021

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

We longitudinally evaluated the tumour growth and metabolic activity of two well-established nasopharyngeal carcinoma (NPC) animal models (C666-1, C17) and three novel models (Xeno76, Xeno23 and NPC43) using a microPET/MR system. With a better understanding of the interplay between tumour growth and metabolic characteristics of these NPC models, we aim to provide insights for the selection of appropriate NPC cell line/xenograft models to assist novel drug discovery and evaluation. MethodsMice were imaged by [ 18 F]FDG microPET/MR twice a week for consecutive 3-7 weeks. [ 18 F]FDG uptake was quanti ed by standardized uptake value (SUV) and presented as SUVmean tumour-to-liver ratio (SUVRmean). Longitudinal tumour growth patterns and metabolic patterns were recorded. SUVRmean and histological characteristics were compared across the ve NPC models. Cisplatin was administrated to one selected optimal tumour model, C17 to evaluate our imaging platform. ResultsWe found variable tumour growth and metabolic patterns across different NPC tumour types. C17 has an optimal growth rate and higher tumour metabolic activity compared with C666-1. C666-1 has a fast growth rate but is low in SUVRmean at endpoint due to necrosis as con rmed by H&E. NPC43 and Xeno76 have relatively slow growth rates and are low in SUVRmean, due to severe necrosis. Xeno23 has the slowest growth rate, and a relative high SUVRmean. Cisplatin showed the expected therapeutic effect in the C17 model in marked reduction of tumour size and metabolism. ConclusionOur study establishes an imaging platform that characterizes the growth and metabolic patterns of different NPC models, and the platform is well able to demonstrate drug treatment outcome supporting its use in novel drug discovery and evaluation for NPC.

show abstract

Section: Discussionsupporting

confidence: 91%

Longitudinal evaluation of five nasopharyngeal carcinoma animal models on the microPET/MR platform

Shi

Xue

Tan

et al. 2021

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

show abstract

“…A human study of indophol alkaloids and chemotherapy drugs cisplatin, investigate the proliferation and migration of nasopharyngeal cancer cells, the combination has a good inhibition of NPC cells, patients, indophol alkaloids also slowed the rela-ted pain of cancer patients, experimental results show that the two have a good effect on the value increase and migration of NPC cells. There is now much research on drugs for nasopharyngeal cancer patients (21). The compatibility of Pabosib (palbociclib) with cisplatin for primary and recurrent nasopharyngeal cancer showed that the combination has significant inhibition of tumour and promotes apoptosis in vivo and in vitro, this combination can further inhibit tumour growth by inducing autophagy-related cell death, where simultaneous palbociclib therapy reduces the cytotoxicity of cisplatin in vitro and reduce adverse reactions in patients.…”

Section: Discussionmentioning

confidence: 99%

Effect of triptolide and chemotherapy on carcinoembryonic and carbohydrate antigens levels and first-line treatment of recurrent nasopharyngeal carcinoma

Liu¹,

Yuan²,

Liu³

et al. 2021

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

To investigate the first-line treatment of recurrent Nasopharyngeal Carcinoma treprimcab combined with chemotherapy. From January 2019 to January 2020, 48 patients with recurrent nasopharyngeal Carcinoma (RNPC) were treated in our hospital. According to the method of the random number, 24 patients were divided into the combined group and the Control Group. The patients in the combined group were given the Combined Treatment of triptolide and chemotherapy. While the Control Group only received chemotherapy. The therapeutic effects and adverse reactions of the two groups were compared, the levels of Carcinoembryonic Antigen (CEA) and carbohydrate Antigen 19-9 (CA19-9) were measured before and after treatment. The total effective rate of the combined group was 79.17% higher than that of the control group (62.50%). The total effective rate of the two groups was statistically significant (P & Lt; 0.05). The incidence of grade i/ii adverse reaction in the control group was lower than that in the combined group, such as nausea and vomiting, oral mucositis, Leukopenia, liver and kidney function damage, central granulocyte count reduction, anaemia adverse reaction. The incidence of grade iii/iv Adr in the control group was higher than that in the combined group. The incidence of grade i/ii Adr in the thrombocytopenia group was higher than that in the combined group, and the incidence of grade iii/iv Adr in the control group was lower than that in the combined group. The side effects of nausea and vomiting and oral mucositis in the control group and the combined group were statistically significant (P & Lt; 0.05). There was no significant difference between the control group and the combined group in the incidence of Leukopenia, liver and kidney injury, neutrophil, anaemia and Thrombocytopenia (P & GT; 0.05). The level of CD4 + / CD8 + in control group and combined group before treatment was higher than that after treatment (P & Lt; 0.05). The quality of life of the combined group was 91.67% higher than that of the control group (70.83%). The quality of life of the control group was significantly higher than that of the combined group (P & Lt; 0.05). The levels of CEA and CA19-9 in the two groups after treatment were lower than those before treatment, and the levels of CEA and CA19-9 in the combined group were lower than those in the control group (P & Lt; 0.05). The first-line treatment of recurrent nasopharyngeal Carcinoma with triprimmab combined with chemotherapy has a good clinical effect and has a broad clinical research prospect.

show abstract

“…372 Palbociclib and SAHA combination therapy also exhibited a synergistic effect in suppressing NPC growth. 373 LY2835219, a selective CDK4/6 inhibitor, inhibited tumor cell proliferation and blocked the cell cycle by suppressing CDK4/6-dependent Ser780 phosphorylation, which showed a potent effect in treating HNSCC. The combination of LY2835219 with a mTOR inhibitor significantly suppressed HNSCC tumor growth in vivo.…”

Section: Egfr Inhibitorsmentioning

confidence: 99%

Targeted therapy for head and neck cancer: signaling pathways and clinical studies

Tie

Alu

et al. 2023

Sig Transduct Target Ther

100

View full text Add to dashboard Cite

Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major risk factors. Based on epigenetic data, HNC is remarkably heterogeneous, and treatment remains challenging. There is a lack of significant improvement in survival and quality of life in patients with HNC. Over half of HNC patients experience locoregional recurrence or distal metastasis despite the current multiple traditional therapeutic strategies and immunotherapy. In addition, resistance to chemotherapy, radiotherapy and some targeted therapies is common. Therefore, it is urgent to explore more effective and tolerable targeted therapies to improve the clinical outcomes of HNC patients. Recent targeted therapy studies have focused on identifying promising biomarkers and developing more effective targeted therapies. A well understanding of the pathogenesis of HNC contributes to learning more about its inner association, which provides novel insight into the development of small molecule inhibitors. In this review, we summarized the vital signaling pathways and discussed the current potential therapeutic targets against critical molecules in HNC, as well as presenting preclinical animal models and ongoing or completed clinical studies about targeted therapy, which may contribute to a more favorable prognosis of HNC. Targeted therapy in combination with other therapies and its limitations were also discussed.

show abstract

Therapeutic Evaluation of Palbociclib and Its Compatibility with Other Chemotherapies in Primary and Recurrent Nasopharyngeal Carcinoma

Cited by 4 publications

References 51 publications

Longitudinal evaluation of five nasopharyngeal carcinoma animal models on the microPET/MR platform

Longitudinal evaluation of five nasopharyngeal carcinoma animal models on the microPET/MR platform

Effect of triptolide and chemotherapy on carcinoembryonic and carbohydrate antigens levels and first-line treatment of recurrent nasopharyngeal carcinoma

Targeted therapy for head and neck cancer: signaling pathways and clinical studies

Contact Info

Product

Resources

About